NDAINTRAVENOUSINJECTABLE
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
FLUDEOXYGLUCOSE F18 (fludeoxyglucose f-18) by Medica Corp is radiopharmaceutical activity [moa]. First approved in 2004.
Drug data last refreshed 2h ago
Mechanism of Action
Radiopharmaceutical Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy
Started Apr 2018
19 enrolled
Stage I Lung CancerStage I Non-Small Cell Lung Cancer AJCC v7Stage IA Non-Small Cell Lung Carcinoma AJCC v7+5 more
Company
Worked on FLUDEOXYGLUCOSE F18 at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.